Episode 20: The Build vs. Buy Question Every Pharma Leader is Wrestling With

<p>We chat with <a href="https://www.linkedin.com/in/karlmoritz/" target="_blank" rel="noopener noreferer">Karl Moritz</a>, CEO of Reliant AI, now part of Cohere, whose career took him from NLP research to McKinsey to building AI infrastructure for drug development. Karl reminds us that clinical trial success rates have been stuck years, and the golden age of AI-powered target discovery isn&#39;t fixing it.</p><p>Karl lays out a sharp framework; own the science, rent the AI plumbing, and explains why building your own data ingestion pipeline is as misguided as writing your own operating system. He&#39;s also candid about what general-purpose LLMs are actually good for, where purpose-built enterprise tools earn their keep, and why the audit trail question will separate serious AI vendors from everyone else. If you&#39;re a pharma or biotech leader trying to make sense of the build vs. buy debate right now, this one is worth your time.</p>